Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biodetection

    Mass Spec Innovations Bring 10M Back to PNNL, Battelle

    By Global Biodefense StaffApril 3, 2015
    Yehia Ibrahim - PNNL Mass Spectrometry Innovations
    Yehia Ibrahim is part of a PNNL team that developed the new Ion Mobility Spectrometry-Mass Spectrometry Proteomics system.
    Share
    Facebook LinkedIn Reddit Email

    A suite of analytical innovations used to detect and measure very low levels of compounds and elements for environmental, national security and health applications has topped $10 million in licensing income for Pacific Northwest National Laboratory and its operator Battelle.

    Since 1989, dozens of PNNL researchers have been enhancing the performance of mass spectrometers — at first for use in PNNL’s own environmental, national security and health-related research programs, and then as part of efforts to improve the science impact of mass spectrometers in the marketplace.

    Mass spectrometry is an ultra-sensitive analytical technique that helps identify and measure the amount and type of elements, molecules and isotopes present in samples ranging from soils to proteins. It’s widely used to analyze samples in the biotechnology, environmental, biofuel, national security, medical and drug testing fields. The technology is used in early detection of disease biomarkers and environmental contaminants, quality assurance and the development of new products.

    Through licenses, PNNL has transferred the technology enhancements to many companies, including Agilent Technologies in Santa Clara, Calif.; Bruker Daltonics in Billerica, Mass.; Thermo Fisher Scientific in San Jose, Calif., and several others. These firms are manufacturing and selling mass spectrometers to customers worldwide.

    Most of the money from these agreements has been directly reinvested in new research programs, demonstration projects, laboratory equipment and staff at the Department of Energy national laboratory in Richland, or reinvested by Battelle in research-related activities consistent with its non-profit mission.

    It’s the first time that income tied to a specific technology developed at PNNL has reached this level. The income was earned from multiple licenses over nearly a 20-year period. The annual amount has steadily increased over the past five years.

    “Based upon the royalty rates in the various licenses, it is estimated that the royalties received by PNNL represent more than 5,000 mass spectrometer instruments sold to date that were based in part on PNNL intellectual property,” said Bruce Harrer, a PNNL commercialization manager.

    “We’ve benefited greatly from PNNL’s developments,” said John Fjeldsted, Agilent Technology’s senior director of ion mobility for Agilent’s Mass Spectrometry Division. “One of the PNNL technologies — the ion funnel — has made significant contributions to the sensitivity of our top-tier products, including those involving ion mobility and time-of-flight measurements.”

    PNNL works with mass spectrometer manufacturers to develop and commercialize these technologies through an active program of collaborative research and development projects. “We have had a number of collaborative R&D projects with PNNL over the past 20 years, many of which have led to important advances in the field,” said Iain Mylchreest, vice president for research and development in Thermo Fisher’s Chromatography and Mass Spectrometry Division.

    Under Battelle’s contract to manage and operate PNNL for DOE, Battelle and DOE may share the costs of bringing a technology to the point that it can be licensed and then share in any proceeds. This long-term partnership has enabled substantial reinvestment in the form of new research projects and additional capabilities at PNNL, such as new mass spectrometer instruments.

    “In addition to advancing scientific discovery, this arrangement is a win-win for taxpayers, DOE and Battelle,” said Cejka. “Taxpayers and society at large benefit from the deployment of new products in the marketplace. The government benefits from the investments made into federally-owned laboratory capabilities. Battelle benefits from the reinvestment of net proceeds into new facilities, equipment, staff capabilities or further research and technology development projects.”

    Images courtesy of Pacific Northwest National Laboratory.

    Battelle Biomarkers
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleChikungunya Virus May Be Coming to a City Near You
    Next Article DARPA BAA – Technologies for Host Resilience (THoR)

    Related Stories

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    SOREX Brings Top CBRNE Units to Dugway Proving Ground

    September 20, 2023

    Biomarkers for Detection of Exposure to Nitrogen Mustards

    September 20, 2023

    Mass Spec for Rapid Detection of Biological Warfare Agents

    September 15, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    Oct 17
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Dispensing and Administration of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.